News
Bristol-Myers Squibb Company announced a significant update in their Sjögren’s Syndrome study. The Phase 3 study tests ...
Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...
Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...
World No. 1 Jannik Sinner has yet to drop a set at the Cincinnati Open heading into the quarterfinals. Sinner will face Felix ...
22h
TipRanks on MSNAmgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3 Randomized, ...
Coco Gauff advanced to the fourth round of the Cincinnati Open after her opponent withdrew due to illness. Gauff will have ...
1d
Clinical Trials Arena on MSNRemeGen’s telitacicept achieves Phase III win in Sjögren’s syndrome
The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...
By HOWARD FENDRICH AP Tennis Writer Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her first Grand Slam competition in two years.
The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...
Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.
The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results